Padwale Vishal, Kirnake Vijendra, Daswani Ravi, Kodmalwar Akshay, Gupta Anusha
Gastroenterology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus. 2024 Jul 17;16(7):e64777. doi: 10.7759/cureus.64777. eCollection 2024 Jul.
Gastric acid-related diseases, including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and () infection, present significant clinical challenges due to their prevalence and potential for severe complications. Effective management of these conditions is essential for symptom relief, mucosal healing, and prevention of complications. This review aims to evaluate the efficacy and safety of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the treatment of gastric acid-related diseases and to compare it with traditional proton pump inhibitors (PPIs). A comprehensive analysis of clinical trials and studies was conducted to assess the effectiveness of vonoprazan in managing GERD, PUD, and infection. The safety profile of vonoprazan was also reviewed, and comparisons were made to PPIs and other gastric acid suppressants. Vonoprazan demonstrates superior and more consistent acid suppression than PPIs, resulting in rapid and sustained symptom relief and mucosal healing. Clinical trials have shown its efficacy in treating GERD, PUD, and infection, with higher eradication rates for H. pylori when used in combination therapies. The safety profile of vonoprazan is favorable, with fewer adverse effects and drug interactions compared to PPIs. Vonoprazan offers a promising alternative to traditional PPIs for the management of gastric acid-related diseases. Its unique mechanism of action and superior efficacy make it a valuable option for patients requiring effective and reliable acid suppression. Further research is warranted to explore its potential in broader clinical applications and to establish long-term safety data.
胃酸相关性疾病，包括胃食管反流病（GERD）、消化性溃疡病（PUD）和（）感染，因其高发病率和严重并发症的可能性而带来重大临床挑战。有效管理这些病症对于缓解症状、黏膜愈合和预防并发症至关重要。本综述旨在评估新型钾竞争性酸阻滞剂（P-CAB）沃克（富马酸伏诺拉生片）治疗胃酸相关性疾病的疗效和安全性，并将其与传统质子泵抑制剂（PPI）进行比较。对临床试验和研究进行了全面分析，以评估沃克治疗GERD、PUD和（）感染的有效性。还对沃克的安全性进行了综述，并与PPI和其他胃酸抑制剂进行了比较。沃克比PPI表现出更优且更持久的抑酸效果，能带来快速且持续的症状缓解和黏膜愈合。临床试验已表明其在治疗GERD、PUD和（）感染方面的疗效，联合治疗时幽门螺杆菌根除率更高。沃克的安全性良好，与PPI相比不良反应和药物相互作用更少。沃克为胃酸相关性疾病的管理提供了一种有前景的传统PPI替代方案。其独特的作用机制和卓越的疗效使其成为需要有效且可靠抑酸的患者的宝贵选择。有必要进一步研究以探索其在更广泛临床应用中的潜力并建立长期安全性数据。
